Figure 6
Nimesulide inhibits SKNO-1 in xenograft and orthotopic AML mouse models. (A) Nimesulide suppresses the formation of xenograft tumors with SKNO-1 cells. Treatment with nimesulide was initiated in NCr nude mice (n = 10) on the day of SKNO-1 cell inoculation. The control group (n = 10) did not receive nimesulide. A total of 20 subcutaneous inoculation sites were tracked in each of the treatment and control groups. The tumor sizes measured on day 25 and are shown as black dots. (B) Nimesulide suppresses the progression of xenograft tumors with SKNO-1 cells. Inoculation of tumor cells was performed as in (A). Treatment with nimesulide was initiated on day 20 after inoculation in the treatment group (black arrow). (C) NSG mice were inoculated via tail vein injections with SKNO-1 cells that have been engineered to express luciferase. Injected mice were fed with normal powder food (square) (n = 5) or normal powder food mixed with nimesulide (dot) (n = 6) from day 6 (black arrow). Progression of SKNO-1 cells was monitored by in vivo imaging of bioluminesce (images are shown in supplemental Figure 6). Results are shown as mean ± SEM. Significant difference in values between the control group and the nimesulide group. *P < .05; Mann-Whitney U test.

Nimesulide inhibits SKNO-1 in xenograft and orthotopic AML mouse models. (A) Nimesulide suppresses the formation of xenograft tumors with SKNO-1 cells. Treatment with nimesulide was initiated in NCr nude mice (n = 10) on the day of SKNO-1 cell inoculation. The control group (n = 10) did not receive nimesulide. A total of 20 subcutaneous inoculation sites were tracked in each of the treatment and control groups. The tumor sizes measured on day 25 and are shown as black dots. (B) Nimesulide suppresses the progression of xenograft tumors with SKNO-1 cells. Inoculation of tumor cells was performed as in (A). Treatment with nimesulide was initiated on day 20 after inoculation in the treatment group (black arrow). (C) NSG mice were inoculated via tail vein injections with SKNO-1 cells that have been engineered to express luciferase. Injected mice were fed with normal powder food (square) (n = 5) or normal powder food mixed with nimesulide (dot) (n = 6) from day 6 (black arrow). Progression of SKNO-1 cells was monitored by in vivo imaging of bioluminesce (images are shown in supplemental Figure 6). Results are shown as mean ± SEM. Significant difference in values between the control group and the nimesulide group. *P < .05; Mann-Whitney U test.

Close Modal

or Create an Account

Close Modal
Close Modal